Jarskog 2009.

Trial name or title	Dehydroepiandrosterone (DHEA) for schizophrenia.
Methods	Allocation: randomised. Blindness: double. Duration: 6 weeks. Funded by Stanley Foundation.
Participants	Diagnosis: schizophrenia, schizoaffective disorder. N = 30. Age: unclear. Sex (M:F): men only. Setting: unclear. History: persistent symptoms with prior adequate trials of antipsychotic drugs. Excluded: unclear. Country: USA.
Interventions	1. DHEA: dose 400 mg/day. 2. Placebo. Other concurrent treatments: unclear, DHEA administered as adjunctive treatment.
Outcomes	Mental state: positive and negative symptoms, psychopathology (PANSS). Global state: CGI. Adverse effects: AIMS.
Starting date	Unclear.
Contact information	Dr L Fredrik Jarskog 1. Department of Psychiatry, University of North Carolina at Chapel Hill CB # 7160 2. Neurosciences Hospital, Chapel Hill, NC 27599 USA Email address: jarskog@med.unc.edu
Notes